N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer’s disease

Ju Youn Lee1,2,3,10, Seung Hoon Han1,2,3,10, Min Hee Park1,2,3, Im-Sook Song4, Min-Koo Choi5, Eunsoo Yu6, Cheol-Min Park6, Hee-Jin Kim7, Seung Hyun Kim7, Edward H. Schuchman8, Hee Kyung Jin1,9✉& Jae-sung Bae1,2,3✉

Sphingosine kinase1 (SphK1) is an acetyl-CoA dependent acetyltransferase which acts on cyclooxygenase2 (COX2) in neurons in a model of Alzheimer’s disease (AD). However, the mechanism underlying this activity was unexplored. Here we show that N-acetyl sphingosine (N-AS) is first generated by acetyl-CoA and sphingosine through SphK1. N-AS then acetylates serine 565 (S565) of COX2, and the N-AS-acetylated COX2 induces the production of specialized pro-resolving mediators (SPMs). In a mouse model of AD, microglia show a reduction in N-AS generation, leading to decreased acetyl-S565 COX2 and SPM production. Treatment with N-AS increases acetylated COX2 and N-AS-triggered SPMs in microglia of AD mice, leading to resolution of neuroinflammation, an increase in microglial phagocytosis, and improved memory. Taken together, these results identify a role of N-AS in the dysfunction of microglia in AD.

1 KNU Alzheimer’s Disease Research Institute, Kyungpook National University, Daegu 41566, South Korea. 2 Department of Physiology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, South Korea. 3 Department of Biomedical Science, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 41944, South Korea. 4 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, South Korea. 5 College of Pharmacy, Dankook University, Cheon-an 31116, South Korea. 6 Department of Chemistry, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, South Korea. 7 Department of Neurology, Hanyang University College of Medicine, Seoul 04763, South Korea. 8 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 9 Department of Laboratory Animal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, South Korea. 10These authors contributed equally: Ju Youn Lee, Seung Hoon Han. ✉email: hkjin@knu.ac.kr; jsbae@knu.ac.kr
Cyclooxygenase2 (COX2), a major factor in inflammatory reactions\(^1\), catalyzes the conversion of its substrates, such as arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), to pro-inflammatory lipid mediators including prostaglandins (PGs), 11-hydroxyeicosatetraenoic acid (HETE)\(^2\), 11-hydroxyeicosapentaenoic acid or 15-hydroxyeicosapentaenoic acid (HEPE)\(^3\), and 13-hydroxydocosahexaenoic acid (HDHA)\(^4,5\). Interestingly, when COX2 is acetylated by acetysalicylic acid (ASA, aspirin), the acetylated COX2 switches its catalytic activity to convert AA, EPA, and DHA to 15-HETE, 18-HEPE, and 17-HDHA, respectively\(^6\). These molecules can be subsequently converted to 15R-lipoxin A4 (15R-LXA4) and resolvins (Rv) E1, D1, D2, and D3, known as specialized pro-resolving mediators (SPMs), in the presence of 5-lipoxygenase (5-LOX)\(^6,7\). SPMs have potent pro-resolving actions, leading to cessation of immune cell infiltration, downregulation of pro-inflammatory and upregulation of anti-inflammatory mediators, and promotion of phagocytosis and tissue regeneration\(^8,9\). Also, recent studies have reported that SPMs are reduced in neuroinflammatory diseases, such as Alzheimer’s disease (AD), resulting in dysfunction of microglia\(^8,9\). However, the mechanisms that underlie the regulation of microglia via SPMs have not been identified in most neuroinflammatory diseases, including AD.

Sphingosine kinase1 (SphK1) is an ATP-dependent lipid kinase that catalyzes the conversion of sphingosine to sphingosine-1-phosphate (S1P)\(^10\). Recently, we demonstrated a role for SphK1 as an acetyl-CoA dependent cytoplasmic acetyltransferase with activity towards COX1\(^11\). We also confirmed that neuronal SphK1 levels are reduced in AD brain, and that increased SphK1 promoted SPM secretion in neurons, especially 15R-LXA4, by acetylating serine residue 565 (S565) of COX2, resulting in improvement of AD-like pathology. However, the biochemical and specific AD pathogenic mechanisms underlying SphK1-mediated COX2 acetylation is not fully understood.

Here, we show that acetyl-CoA binds the ATP binding site in SphK1, and that reaction of acetyl-CoA and sphingosine within SphK1 generates N-acetyl sphingosine (N-AS). N-AS is acetylated by SphK1 binds COX2, and acetylates the S565, which corresponds to the residue we previously showed was acetylated by SphK1 in our previous study\(^11\) (Fig. 1c, d). When COX2 was acetylated by N-AS, the same site that we found acetylated by SphK1 in our previous study\(^11\) (Fig. 1c, d). From these studies we found that N565 on peptide 565-GCPFTSFSVPDPELIK-575 of COX2 was acetylated in the presence of N-AS, the same site that we found acetylated by SphK1 in our previous study\(^11\) (Fig. 1c, d). To further characterize acetylated S565 of COX2 by N-AS, we generated rabbit polyclonal and mouse monoclonal antibodies, ac-S565. Inactivation of COX2 with N-AS led to strong ac-S565-positive signals in western blot analyses compared with naïve COX2 and aspirin-treated COX2 (Fig. 1e). Projection of the acetylation site on the theoretical crystal structure of human COX2 showed that S565 was located on the catalytic domain of the enzyme\(^12\) and in the vicinity of asparagine 181 (N181), threonine 564 (T564), and serine 567 (S567) (Fig. 1f). Based on the theoretical crystallographic model, we propose a possible mechanism of N-AS-acetylated COX2 in which acetyl transfer to S565 in the COX2 active site via N-AS was promoted by the hydrogen bonding of N181 and T564 with the acetyl group. Additional hydrogen bonding of S567 with the C3 hydroxyl group appeared to further increase the binding affinity of N-AS (Fig. 1g). To establish the validity of this mechanism, we mutated residues S565, N181, T564, and S567 of COX2 and performed kinetic and acetylation analysis. The binding affinity and acetylation of COX2 were significantly decreased in the mutant COX2, including S565A, N181A, T564A, and S567A, compared with COX2 WT. Interestingly, S565A showed the lowest binding affinity and acetylation level compared to the other mutants, suggesting that S565 is the main target site of N-AS-mediated COX2 acetylation (Fig. 1a, h).

### Results

**Residue S565 of COX2 is acetylated by N-AS.** To further study the role of N-AS as an intermediate in SphK1-mediated COX2 acetylation, we performed a binding assay of N-AS to COX2. Incorporation of N-AS to COX2 became saturated with increased concentrations of N-AS, yielding \(K_M\) and \(K_{cat}\) values of 35.48 µM and 0.51 min\(^{-1}\), respectively (Fig. 1a). We also measured the acetylation level of COX2 in the presence of \([\text{\textsuperscript{14}}C]\) N-AS. N-AS-mediated COX2 acetylation displayed higher-level acetylation compared with aspirin or SphK1-mediated COX2 acetylation (Fig. 1b). These results indicated that N-AS, as an intermediate for SphK1-mediated COX2 acetylation, had high binding affinity and induced high-level acetylation of COX2.

Next, to identify which site on COX2 was acetylated by N-AS, we treated N-AS with COX2. From these studies we found that S565 on peptide 565-GCPFTSFSVPDPELIK-575 of COX2 was acetylated in the presence of N-AS, the same site that we found acetylated by SphK1 in our previous study\(^11\) (Fig. 1c, d). To further characterize acetylated S565 of COX2 by N-AS, we generated rabbit polyclonal and mouse monoclonal antibodies, ac-S565. Inactivation of COX2 with N-AS led to strong ac-S565-positive signals in western blot analyses compared with naïve COX2 and aspirin-treated COX2 (Fig. 1e). Projection of the acetylation site on the theoretical crystal structure of human COX2 showed that S565 was located on the catalytic domain of the enzyme\(^12\) and in the vicinity of asparagine 181 (N181), threonine 564 (T564), and serine 567 (S567) (Fig. 1f). Based on the theoretical crystallographic model, we propose a possible mechanism of N-AS-acetylated COX2 in which acetyl transfer to S565 in the COX2 active site via N-AS was promoted by the hydrogen bonding of N181 and T564 with the acetyl group. Additional hydrogen bonding of S567 with the C3 hydroxyl group appeared to further increase the binding affinity of N-AS (Fig. 1g). To establish the validity of this mechanism, we mutated residues S565, N181, T564, and S567 of COX2 and performed kinetic and acetylation analysis. The binding affinity and acetylation of COX2 were significantly decreased in the mutant COX2, including S565A, N181A, T564A, and S567A, compared with COX2 WT. Interestingly, S565A showed the lowest binding affinity and acetylation level compared to the other mutants, suggesting that S565 is the main target site of N-AS-mediated COX2 acetylation (Fig. 1a, h).

**N-AS induces production of SPMs by COX2 acetylation.** To investigate the production of SPMs by N-AS-acetylated COX2, we performed COX2 product profiling for AA, EPA, and DHA using recombinant COX2 treated with N-AS in the presence of 5-LOX (Supplementary Table 1). Consistent with previous studies, including ours\(^2,7,11\), N-AS-treated COX2 significantly increased 15-HETE, 18-HEPE, and 17-HDHA, known as SPM precursors\(^6,7\), compared with naïve COX2 and aspirin-treated COX2 (Fig. 2a and Supplementary Table 1). Moreover, the N-AS treated COX2 reduced PGs, such as PGH3 (Supplementary Table 1). Next, several SPMs were identified using LC-MS/MS. Interestingly, SPMs, including 15R-LXA4, RvE1, and RvD1, were produced by N-AS-acetylated COX2 (Fig. 2b). The level of SPMs induced by N-AS exhibited a marked increase compared with those produced by COX2 without treatment, and was similar to those produced by aspirin (Fig. 2c). To gain more direct insights into the relationship of N-AS-acetylated COX2 and SPM production, we verified the production of SPMs in the COX2 S565A mutant. The S565A mutant led to considerably decreased production of SPMs after treatment of N-AS,
although there were no differences after treatment with aspirin, indicating that S565 in N-AS-acetylated COX2 is important for production of SPMs (Fig. 2c). Overall, we confirmed that N-AS-acetylated COX2 produced SPMs, suggesting the potential pathological role and therapeutic use of N-AS in inflammatory diseases, including AD.

\[\text{Aβ induce loss of N-AS generation in neuron and microglia.}
\] Previously, SphK1-mediated COX2 acetylation was observed in neurons, and was found to be decreased in neurons derived from AD11, suggesting that N-AS produced by SphK1 might be important for central nervous system (CNS) cells. To investigate the generation and roles of N-AS in CNS cells, primary culture of...
includes N-AS in AD microglia, and might be treated by N-AS supplementation. The binding velocity ($V_{\text{binding}}$) of [14C] N-AS to COX2 was plotted to the N-AS concentration and the nonlinear regression analysis of the saturated plot yielded the kinetic parameters such as $K_{\text{cat}}$ (catalytic constant) and $K_{m}$ (Michaelis-Menten constant) for N-AS and COX2 binding activity ($n = 3$ independent experiments per group). b Acetylation assay of purified COX2 protein treated with [14C] N-AS. The purified COX2 protein incubated in the presence of [14C] N-AS for 2 h at 37°C and then COX2 was analyzed on scintillation counter. [14C] aspirin-treated COX2 protein and [14C] acetyl-CoA treated COX2 protein with SphK1 and sphingosine were positive control ($n = 6–9$ per group). c LC-MS spectra of peptide 560-GCPTTFSVPDPELIK-575 (m/z = 918.94) of COX2 acetylated by N-AS. d LC-MS/MS spectra of ac-S565 in 560-GCPTTFSVPDPELIK-575 of COX2. e Recombinant COX2 protein was incubated in the presence or absence of 2 mM N-AS or aspirin as indicated and S565 acetylation was determined by western blotting using anti-ac-S565 and COX2 antibodies. Data were replicated in six independent experiments with similar results. f The theoretical crystallographic model of human COX2 structure was taken from Protein Data Bank file 1VOX. S565 and residues (N181, T564, and S567) involved in the catalysis of COX2 were projected on the crystal structure of COX2 using PyMOL. Residues are shown as well: (1) S565 (red); (2) N181, T564, and S567 (green). g Proposed mechanism for the acetylation of S565 of COX2 by N-AS. h Acetylation assay of COX2 WT, COX2 S565A, COX2 N181A, COX2 T564A, and COX2 S567A treated with [14C] N-AS. ($n = 6$ independent experiments per group). b, h One-way analysis of variance, Tukey’s post hoc test. All error bars indicate s.e.m. Source data are provided as a Source data file.

**Fig. 1 N-AS acetylates S565 in COX2.** a N-AS binding activity of COX2 WT, COX2 S565A, COX2 N181A, COX2 T564A, and COX2 S567A was analyzed by filter binding assay. The binding velocity ($V_{\text{binding}}$) of [14C] N-AS to COX2 was plotted to the N-AS concentration and the nonlinear regression analysis of the saturated plot yielded the kinetic parameters such as $K_{\text{cat}}$ (catalytic constant) and $K_{m}$ (Michaelis-Menten constant) for N-AS and COX2 binding activity ($n = 3$ independent experiments per group). b Acetylation assay of purified COX2 protein treated with [14C] N-AS. The purified COX2 protein incubated in the presence of [14C] N-AS for 2 h at 37°C and then COX2 was analyzed on scintillation counter. [14C] aspirin-treated COX2 protein and [14C] acetyl-CoA treated COX2 protein with SphK1 and sphingosine were positive control ($n = 6–9$ per group). c LC-MS spectra of peptide 560-GCPTTFSVPDPELIK-575 (m/z = 918.94) of COX2 acetylated by N-AS. d LC-MS/MS spectra of ac-S565 in 560-GCPTTFSVPDPELIK-575 of COX2. e Recombinant COX2 protein was incubated in the presence or absence of 2 mM N-AS or aspirin as indicated and S565 acetylation was determined by western blotting using anti-ac-S565 and COX2 antibodies. Data were replicated in six independent experiments with similar results. f The theoretical crystallographic model of human COX2 structure was taken from Protein Data Bank file 1VOX. S565 and residues (N181, T564, and S567) involved in the catalysis of COX2 were projected on the crystal structure of COX2 using PyMOL. Residues are shown as well: (1) S565 (red); (2) N181, T564, and S567 (green). g Proposed mechanism for the acetylation of S565 of COX2 by N-AS. h Acetylation assay of COX2 WT, COX2 S565A, COX2 N181A, COX2 T564A, and COX2 S567A treated with [14C] N-AS. ($n = 6$ independent experiments per group). b, h One-way analysis of variance, Tukey’s post hoc test. All error bars indicate s.e.m. Source data are provided as a Source data file.

**Fig. 1 N-AS acetylates S565 in COX2.** a N-AS binding activity of COX2 WT, COX2 S565A, COX2 N181A, COX2 T564A, and COX2 S567A was analyzed by filter binding assay. The binding velocity ($V_{\text{binding}}$) of [14C] N-AS to COX2 was plotted to the N-AS concentration and the nonlinear regression analysis of the saturated plot yielded the kinetic parameters such as $K_{\text{cat}}$ (catalytic constant) and $K_{m}$ (Michaelis-Menten constant) for N-AS and COX2 binding activity ($n = 3$ independent experiments per group). b Acetylation assay of purified COX2 protein treated with [14C] N-AS. The purified COX2 protein incubated in the presence of [14C] N-AS for 2 h at 37°C and then COX2 was analyzed on scintillation counter. [14C] aspirin-treated COX2 protein and [14C] acetyl-CoA treated COX2 protein with SphK1 and sphingosine were positive control ($n = 6–9$ per group). c LC-MS spectra of peptide 560-GCPTTFSVPDPELIK-575 (m/z = 918.94) of COX2 acetylated by N-AS. d LC-MS/MS spectra of ac-S565 in 560-GCPTTFSVPDPELIK-575 of COX2. e Recombinant COX2 protein was incubated in the presence or absence of 2 mM N-AS or aspirin as indicated and S565 acetylation was determined by western blotting using anti-ac-S565 and COX2 antibodies. Data were replicated in six independent experiments with similar results. f The theoretical crystallographic model of human COX2 structure was taken from Protein Data Bank file 1VOX. S565 and residues (N181, T564, and S567) involved in the catalysis of COX2 were projected on the crystal structure of COX2 using PyMOL. Residues are shown as well: (1) S565 (red); (2) N181, T564, and S567 (green). g Proposed mechanism for the acetylation of S565 of COX2 by N-AS. h Acetylation assay of COX2 WT, COX2 S565A, COX2 N181A, COX2 T564A, and COX2 S567A treated with [14C] N-AS. ($n = 6$ independent experiments per group). b, h One-way analysis of variance, Tukey’s post hoc test. All error bars indicate s.e.m. Source data are provided as a Source data file.

**Generation and function of N-AS is reduced in AD microglia.** Next, to assess the generation and roles of N-AS in AD pathogenesis, we first determined N-AS generation in microglia and neurons derived from WT mice and APP/PS1 mice. N-AS was detected in microglia and neurons derived from WT mice, and decreased in those derived from APP/PS1 mice compared with WT mice (Fig. 4b). Specificity of ac-S565 COX2 immunoreactivity was also observed in microglia and neurons of WT mice, and significantly reduced in microglia and neurons of APP/PS1 mice compared with WT mice (Fig. 4c, d and Supplementary Fig. 4a). Consistent with CNS cell studies above, the levels of N-AS and acetyl-S565 COX2 were higher in microglia than in neurons, suggesting N-AS-acetylated COX2 was more active in microglia than in neuron. These results indicated that N-AS might play important roles in microglia of AD. In addition, to assess the influence of N-AS in AD pathogenesis, we injected N-AS daily subcutaneously (s.c.) for 8 weeks to 7-months-old APP/PS1 mice until the age of 9 months (Fig. 4a). In APP/PS1 mice treated with N-AS, the levels of N-AS and N-AS-mediated COX2 acetylation were more restored in microglia of APP/PS1 mice compared with those in neurons (Fig. 4b–d and Supplementary Fig. 4a). These data indicated that microglia were the likely target cells responsible for AD pathogenesis via N-AS.

To further investigate why AD pathology was more dependent on N-AS in microglia compared to neurons, we first assessed expression of COX2 in microglia and neurons. COX2 expression was significantly increased in APP/PS1 microglia compared with WT microglia beginning at 5 months of age. In contrast to the microglia, no significant differences in COX2 expression was observed in neurons (Supplementary Fig. 4b, c). Next, to confirm whether N-AS was bound to and acetylated COX2 in the APP/PS1 microglia and neurons, we isolated microglia and neurons after [14C] N-AS administration to WT and APP/PS1 mice, and checked [14C] radioactivity of COX2 purified from these cells. We found that [14C] N-AS was more avidly bound to and acetylated COX2 of APP/PS1 microglia compared with COX2 in WT microglia; no significant differences were observed in neurons (Supplementary Fig. 4d). These results indicated that the high COX2 expression of microglia might be prone to increased binding and acetylation by N-AS compared with that in neurons in APP/PS1 mice.

Finally, to assess the ability of N-AS-acetylated COX2 to produce SPMs in microglia of APP/PS1 mice, we performed lipidomic profiling analysis in microglia derived from WT, APP/PS1, and APP/PS1 mice treated with N-AS (Supplementary Table 2). The SPM precursors, including 15-HETE, 18-HEPE, and 17-HDHA, were decreased in APP/PS1 microglia versus WT microglia. However, microglia derived from APP/PS1 mice treated with N-AS had levels that were restored to those of WT microglia, and might be treated by N-AS supplementation.
Consistent with these observations, the SPMs themselves, such as 15R-LXA4, RvE1, and RvD1, exhibited a marked decrease in microglia derived from APP/PS1 mice compared with microglia derived from WT mice. These levels were restored in microglia derived from APP/PS1 mice treated with N-AS (Supplementary Fig. 4f, g; Supplementary Table 2). Taken together, these results demonstrated that N-AS generation was mainly decreased in microglia of APP/PS1 mice, which resulted in reduced acetyl-S565 COX2 and SPM expression, and N-AS treatment led to potent anti-inflammatory actions by inducing N-AS-triggered SPMs via S565 acetylation of COX2.
N-AS-triggered SPMs regulate microglial characterization. To investigate the direct effect of N-AS-triggered SPMs on microglial regulation, we first examined microglial activation by determining the activities of pro-inflammatory (CD86) or anti-inflammatory (CD206) molecules, in WT, APP/PS1, and N-AS-treated APP/PS1 mice. The CD206 molecules were abundant in APP/PS1 mice treated with N-AS compared with APP/PS1 mice treated with vehicle, indicating that N-AS-induced SPMs improved the anti-inflammatory activity of microglia in APP/PS1 mice (Fig. 4e).

Next, to further examine the regulation of microglia by N-AS-triggered SPMs, we analyzed the gene expression patterns of microglia derived from WT, APP/PS1, and N-AS-injected...
APP/PS1 mice using RNA seq. Comparative RNA seq analysis revealed that APP/PS1 microglia expressed high levels of genes that induced an inflammatory response (e.g., Spp1, Il6, Il10, Il1b, Tnfa, Cxcl10, Cxcl12, Ccl2, Csf1, and Mmp1) and suppressed homeostatic genes (e.g., Fa2h, Cidea, Neurod1, Gck, Epor, and Atp7b) compared with WT microglia (with <2 Z-score and P < 0.05). These results confirmed the characteristics of the microglial neurodegenerative phenotype of APP/PS1 mice determined in previous studies. Interestingly, microglia derived from APP/PS1 mice treated with N-AS showed upregulation of several reactive microglial genes (e.g., Rap1gap, Tbxh, Mx3h, Appl1, Adam8, and Megf10) linked to phagocytosis and downregulation of inflammatory and immune molecules (e.g., Spp1, Il10, Il1b, Tnfa, Cxcl12, Ccl2, Csf1, and Mmp1) compared with microglia derived from APP/PS1 treated with vehicle, indicating improvement of the microglial neurodegenerative phenotype of APP/PS1 mice. Furthermore, functional categorization using the DAVID bioinformatics database for GO term enrichment analysis (biological process and molecular function) demonstrated that the differentially expressed genes in microglia of N-AS-treated APP/PS1 mice compared with APP/PS1 were strongly associated with an inflammatory response, immune response, and phagocytosis (Fig. 4g, h). KEGG pathway analysis identified a considerable enrichment of genes involved in phagocytosis (e.g., lysosome and phagosome) and immune response (e.g., cytokine–cytokine receptor interaction and chemokine signaling pathway) (Fig. 4i). These results indicated that N-AS-triggered SPMS activated an anti-inflammatory, positive immune response, and enhanced the phagocytic abilities of microglia in N-AS-treated APP/PS1 mice, leading to resolution of neuroinflammation and upregulation of phagocytic microglia in this AD animal model.

SPMs regulate microglial phagocytosis and immune response. Based on RNA seq results, we next examined whether the enhancement of phagocytic microglia resulted from N-AS-triggered SPMS and promoted Aβ phagocytosis in N-AS-treated APP/PS1 mice. First, to determine whether N-AS-triggered SPMS restored microglial recruitment to Aβ, we quantified the number of microglia surrounding the plaques, and found that microglial recruitment was increased in APP/PS1 mice treated with N-AS compared to APP/PS1 mice treated with vehicle (Fig. 5a). We next performed a phagocytosis assay using live brain slices of WT, APP/PS1 mice injected with vehicle and APP/PS1 injected with N-AS mice. More phagocytic microglia were found in APP/PS1 mice treated with N-AS compared to APP/PS1 mice treated with vehicle, using a fluorescent bead phagocytosis assay (Fig. 5b). To further investigate this effect, the Aβ phagocytic activity of microglia was evaluated in APP/PS1 mice treated with vehicle and APP/PS1 treated with N-AS mice. APP/PS1 mice treated with N-AS showed demonstrably increased number of microglia containing co-stained lysosomes and Aβ compared to APP/PS1 mice treated with vehicle (Supplementary Fig. 5a). Also, we performed morphological characterization of microglia surrounding Aβ in APP/PS1 mice treated with vehicle and APP/PS1 treated with N-AS mice, and found that the phagocytic morphology (ameboid microglial morphology) was more evident in APP/PS1 mice treated with N-AS than APP/PS1 mice treated with vehicle, indicating increased Aβ phagocytosis (Supplementary Fig. 5b). Next, because the immunohistochemistry analysis could not functionally distinguish between increased phagocytosis and impaired degradation, we analyzed the expression of Aβ degrading enzymes, including neprilysin (NEP), matrix metallopeptidase 9 (MMP9), and insulin-degrading enzyme (IDE), in WT, APP/PS1 mice injected with vehicle and APP/PS1 injected with N-AS mice. These enzymes remained unchanged between the groups, whereas CD36, which is known to be increased in phagocytic microglia, was enhanced in APP/PS1 mice treated with N-AS (Supplementary Fig. 5c). Finally, in Aβ plaque morphometric analysis, APP/PS1 mice treated with N-AS, rather than APP/PS1 mice treated with vehicle, showed significantly increased number of small (<25 μm) plaques, and a significant reduction of medium (25–50 μm) and large-sized (>50 μm) plaques, indicating that the outer parts of the Aβ aggregates was phagocytosed by microglia (Supplementary Fig. 5d). Overall, these results demonstrated that N-AS-triggered SPMS elevated the phagocytic capacity of microglia, and enhanced the microglial Aβ phagocytic function in APP/PS1 mice.

SPMS can stimulate the resolution of inflammation by regulating immune cells, such as limiting neutrophil infiltration and enhancing the clearance of debris by macrophages, and have been shown to contribute to disease pathogenesis. These blood-derived immune cells might be promoted by Aβ, and have been shown to contribute to disease pathogenesis. Interestingly, the numbers of pro-inflammatory macrophages, monocytes, neutrophils, and CD4+ T cells into the brain compared with WT mice (Fig. 5c–g). Elevated levels of macrophages, pro-inflammatory monocytes, and CD4+ T cells, and decreased levels of anti-inflammatory monocytes were also present in blood of APP/PS1 mice compared with WT (Supplementary Fig. 5e–i), similar to findings in a previous study. These blood-derived immune cells might be promoted by Aβ, and have been shown to contribute to disease pathogenesis. These blood-derived immune cells might be promoted by Aβ, and have been shown to contribute to disease pathogenesis. These blood-derived immune cells might be promoted by Aβ, and have been shown to contribute to disease pathogenesis.
N-AS-triggered SPMs in microglia positively regulated the immune system of brain and blood, although lymphocytes, such as CD4+ T cells and B220+ B cells, did not change. Our results supported the concept that N-AS-triggered SPMs modulated microglial Aβ phagocytic function and resolved neuroinflammation via regulation of the immune system, suggesting the potential therapeutic possibilities of N-AS as a direct microglial regulator and immunomodulator in neuroinflammatory diseases, including AD. 

**N-AS-triggered SPMs improve AD pathology in APP/PS1 mice.** Finally, to determine whether microglia regulation by
N-AS-triggered SPMs in APP/PS1 AD mice affected pathology, we first determined the Aβ profile in APP/PS1 mice treated with vehicle and APP/PS1 treated with N-AS mice. Thioflavin S (ThioS) staining, immunofluorescence of 6E10, Aβ40, and Aβ42, and ELIs of Aβ40 and Aβ42 showed significantly lower Aβ levels in the APP/PS1 mice treated with N-AS compared to APP/PS1 mice treated with vehicle (Fig. 6a–e). In APP/PS1 mice treated with N-AS, cerebral amyloid angiopathy and tau hyperphosphorylation were also reduced (Fig. 6f, g). Moreover, the inflammatory response was improved in the APP/PS1 mice treated with N-AS compared to APP/PS1 mice treated with vehicle (Fig. 6h–j). Overall, these data indicated that N-AS-induced SPMs reduced Aβ plaque burden and neuroinflammation via upregulating phagocytic microglia and positive regulation of the immune response.

Next, to investigate neuropathology improvement by microglia regulation of N-AS-triggered SPMs, we performed immunolabeling for synaptophysin, MAP2, synapsin1, and PSD95 in WT, APP/PS1, and N-AS-treated APP/PS1 mice. The labeling densities of synaptophysin, MAP2, synapsin1, and PSD95 were reduced in APP/PS1 mice compared with those in WT mice. However, the expression levels of synaptophysin, MAP2, synapsin1, and PSD95 were restored in APP/PS1 mice treated with N-AS compared with those in APP/PS1 mice (Supplementary Fig. 7a–d). We also performed the Morris water maze test and fear conditioning in WT, APP/PS1 injected with vehicle and APP/PS1 injected with N-AS mice to examine changes in learning and memory. The APP/PS1 mice treated with vehicle showed severe deficits in memory formation, while APP/PS1 mice treated with N-AS were largely protected from this defect (Fig. 6k–q and Supplementary Fig. 7e). For locomotion and spontaneous activity, open field and light-dark tests were used. APP/PS1 mice treated with N-AS showed improved locomotion and spontaneous activity in the open field test compared with APP/PS1 mice, although the light–dark test did not differ between the groups (Supplementary Fig. 7f–n). These results showed that N-AS-triggered SPMs restored neuropathology and led to behavioral improvement in APP/PS1, which might be caused by increased Aβ phagocytosis via N-AS-treated microglia. However, apoptosis was not changed in the N-AS treated APP/PS1 mice compared with the vehicle treated APP/PS1 mice, although N-AS has been used extensively to induce apoptosis of tumors18,19 (Supplementary Fig. 7o). Unlike nonsteroidal anti-inflammatory drugs including aspirin20, the mRNA and protein levels of COX2 did not vary between APP/PS1 mice and N-AS-treated APP/PS1 mice, indicating that reduction of COX2 expression was not responsible for the restoration of AD pathology (Supplementary Fig. 7p, q). To confirm the findings above, we repeated these studies in another mouse model of AD, 5×FAD mice, and found that N-AS treatment similarly improved AD pathology of 5×FAD mice, including Aβ plaque deposit, Aβ plaque phagocytosis, neuroinflammation, and synapse activity (Supplementary Fig. 8). Collectively, these results indicated that N-AS treatment attenuated AD pathology by regulating microglia via N-AS-triggered SPMs, but not by inducing apoptosis and decreasing COX2 expression.

Discussion
Here, we investigated the specific mechanism of SphK1-mediated COX2 acetylation, which led to production of SPMs and resolution of neuroinflammation in microglia of AD. In SphK1-mediated COX2 acetylation, acetyl-CoA bound the ATP binding pocket of SphK1, and the acetyl group of acetyl-CoA was transferred to sphingosine, resulting in the generation of N-AS. In turn, N-AS then acetylated residue S565 of COX2, forming an intermediate between SphK1 and COX2. N-AS-acetylated COX2 led to production of SPMs, including 15R-LXA4, RvE1, and RvD1, in the presence of 5-LOX, suggesting the potential pathological roles and therapeutic use of N-AS in inflammatory diseases (Supplementary Fig. 9a). Interestingly, we demonstrated that the reduction of N-AS generation is found mainly in microglia of the AD brain, leading to decreased acetyl-S565 COX2 and SPM production. The decreased N-AS-triggered SPMs caused failure of neuroinflammatory resolution and reduced phagocytosis ability, leading to an increase in immune cell trafficking and plaque burden, which exacerbated AD pathology. Moreover, N-AS administration into AD mice increased N-AS-triggered SPMs by S565 acetylation of COX2, especially in microglia, resulting in increase of phagocytic microglia. The phagocytic microglia led to resolution of neuroinflammation and an increase of Aβ phagocytosis, ameliorating AD pathology (Supplementary Fig. 9b). Collectively, our findings establish a biosynthetic mechanism and role of N-AS in AD pathogenesis, and established “proof-of-concept” for N-AS treatment in neuroinflammatory diseases including AD.

We previously demonstrated the role of neuronal SphK1-acetyltransferase activity on COX2 and showed that it was reduced in AD neurons, exacerbating AD pathology11. However, the mechanism of SphK1-mediated COX2 acetylation remained poorly understood, as well as its role in the pathogenesis of AD. In this study, we established N-AS as intermediate of SphK1-mediated COX2 acetylation. The N-AS was generated in neurons and microglia, which was abrogated by Aβ in the AD environment. The reduction of N-AS generation in AD neurons was caused by decreased SphK1 activity, while reduced N-AS synthesis in AD microglia was caused by deficient acetyl-CoA. Of note, a reduction of acetyl-CoA was previously found to be associated with mitochondrial dysfunction, such as inhibited pyruvate dehydrogenase complex activity, through oxidative damage by Aβ in the brains of AD 2576Tg and 3xTg mice, leading to defective microglia21,22. However, the correlation of microglia dysfunction
and acetyl-CoA metabolism has not been fully understood. In our study, decreased N-AS generation by deficient acetyl-CoA in AD microglia induced reduction of COX2 acetylation and SPM expression, resulting in neurodegenerative microglia. Based on previous studies and our results, we propose that deficient acetyl-CoA metabolism by Aβ destroys microglia in AD through reduction of N-AS generation.

Although there is extensive literature supporting the importance of microglial regulation in the pathogenesis of AD, the precise regulator(s) of microglia remains to be explored in AD. The SPMs, such as RvD1 and LXA4, play an important role in the maintenance of phagocytic microglia, and are reduced in AD brain, suggesting the possibility of SPMs as microglial regulators. Further, in a previous study, we reported the loss of SphK1 activity and reduced SPM secretion in AD neurons, which led to defective microglial phagocytosis and dysfunction of inflammation resolution, indicating the indirect regulation of microglia by neurons. In this study, our results showed that N-AS was mainly observed in microglia of N-AS-treated APP/PS1 mice rather than neurons, and directly regulated microglia via N-AS-triggered SPMs. The N-AS-triggered SPMs derived from microglia upregulated several reactive microglial genes linked to...
phagocytosis, and downregulated several inflammatory and immune molecules in microglia of N-AS-treated APP/PS1 mice. We also confirmed that N-AS-triggered SPMs derived from microglia resolves neuroinflammation via regulation of the immune system, similar to the function of SPMs reported in previous studies. Furthermore, we confirmed that N-AS-triggered SPMs produced from microglia directly mediate the effects seen after administration of N-AS. When 5-LOX inhibitor, zileuton, was incubated with N-AS in Aβ-treated human microglia, the production of N-AS-triggered SPMs and restoration of phagocytic capacity was inhibited, indicating that N-AS-triggered SPMs directly mediate the positive effects in microglia. However, because the zileuton also reduce formation of leukotriene (e.g., LTB4) and prostaglandin (e.g., PGE2) production, we cannot completely rule out the possibility that blocking 5-LOX may result in the reduction of other lipid mediators that may have effects on phagocytosis. Our results showed that zileuton treatment reduced PGE2, as well as SPMs, although LTB4 was not detected. Both SPMs and PGE2, which decreased by zileuton, play an important role in phagocytic ability of microglia, and phagocytosis is restored through the increase of SPMs production and inhibition of PGE2 synthesis. In our study, although the levels of PGE2 were decreased, the phagocytic ability was not restored by N-AS in Aβ-treated microglia with zileuton. These results suggest the N-AS-triggered SPMs, rather than the other lipid mediators, were more responsible direct regulation of microglia including phagocytosis in AD environment. Notably, N-AS-triggered SPMs, as well as N-AS generation and acetyl-S565 COX2, in microglia were higher than those in neurons, suggesting that the N-AS-triggered SPMs derived from microglia might play an important role rather than those derived from neurons. Collectively, these results indicated that direct microglial regulation via N-AS-triggered SPMs derived from microglia might be more responsible for AD pathogenesis than indirect regulation of microglia thorough neurons, suggesting N-AS-triggered SPMs derived from microglia as direct regulators of pathology in AD.

In AD diagnosis, positron emission tomography (PET) imaging procedures are used for detecting Aβ and tau material when molecular aggregates are deposited in the brain at high concentration in the late stages of AD pathology. However, it is very difficult to diagnosis the disease before the protein aggregates. The neuroinflammation in the AD pathology starts at very early stages, most likely before amyloid plaques are formed, suggesting it may be a promising therapeutic target and useful in the diagnosis of AD at preclinical stages. In fact, use of radiolabeled translocator protein (TSPO, first described as the peripheral benzodiazepine receptor) ligands to quantify the expression of the microglial TSPO receptor has been applied for the diagnosis of neuroinflammation. Similar to radiolabeled TSPO ligands, N-AS might be considered to diagnose neuroinflammation in early AD stages, in addition to its potential therapeutic use, based on two results: (1) In PK profiling of N-AS, a high concentration of N-AS was maintained in plasma and brain, and N-AS had high-distribution to the brain; and (2) N-AS had high binding affinity and induced high-level acetylation of the elevated COX2, prior to observing Aβ deposits in APP/PS1 microglia. Despite the potential of N-AS as a therapeutic, it is also important to recognize that this therapeutic use of N-AS may be limited by its poor solubility and low BA. There is also the potential of N-AS to induce apoptosis, which has been found in other studies. Therefore, additional studies are warranted to investigate derivatives of N-AS that might be potentially useful for neuroinflammatory diseases including AD.

**Methods**

**Molecular docking.** Molecular modeling studies were performed using Discovery Studio Programs (2018, Accelrys) and figures were generated using PyMOL programs. The 3D coordinates of human SphK1 complexed with ADP were obtained from the protein data bank for docking studies (PDB entry 3V2D). 3V2D represents a tetrameric crystal structure of SphK1 that includes six monomers (A-F). Monomer C was chosen for the simulations based on its displacement property. ADP, which binds between the N-terminal and C-terminal domains, was removed from the complex. Preparation of the protein was performed with the Prepare Protein protocol and a binding site was created using the Define and Edit Binding Site protocol (default parameters were used). Energy minimization of ligands was performed by the Clean Geometry module in Discovery Studio, and conformations were generated using the Generate Conformations protocol and the Best method. The 3D structure of SphK1 was then verified using VEGA.Z and Edit Binding Site protocol (default parameters were used) to confirm the binding orientation and consistency of the ligands (acetyl-CoA, sphingosine, and ATP) was performed using the CDOCKER protocol, and analysis of ligand interactions at the binding site was performed using the ligand Interactions tool followed by visual inspection.

**SIP assays.** We confirmed SIP formation through SphK1 enzymatic activity measurements as previously described using a UPLC (Ultra performance liquid chromatography) system (Waters). Briefly, 3 μl of SphK1 (Cayman, 10348) were mixed with 3 μl of assay buffer (200 μM NBD-sphingosine (Avanti Polar Lipids), 100 mM of HEPES buffer, pH 7.2, 10 mM MgCl2, 200 mM Semicarbazide, 1 mM 4-deoxyribozon, 2 mM Dithiothreitol, and 0.2% (Igepal CA-630, all from Sigma-Aldrich) in the presence of 0–50 mM acetyl-CoA (Sigma-Aldrich, A2056), and the mixture was pre-incubated at 37 °C for 10 min. After pre-incubation, 1 mM ATP (Amresco, 0220) was added the mixture, and it was incubated at 37 °C for 1 h. The hydrolysis reactions were stopped by adding 53 μl of ethanol, and centrifuged at 15,493g for 5 min. Thirty microliter of the supernatant was then transferred to a 96-well glass vial and 5 μl was added upon a UPLC system for analysis. SIP formation was followed as phosphorylation of (7-nitro-2-1,3-benzoxadiazol-4-yl) d-erythro (NBD)-sphingosine.
Fig. 6 Administration of N-AS reduces amyloid pathology and restores cognitive function in APP/PS1 mice by N-AS-triggered SPMs. a Left, representative immunofluorescence images of thioflavin S (ThS, Aβ plaques) in cortex and hippocampus of APP/PS1 and APP/PS1 treated with N-AS mice. Scale bars, 100 µm. Right quantification of area occupied by Aβ plaques (APP/PS1 mice, n = 9; APP/PS1 + N-AS mice, n = 8). b Quantification of 6E10 in cortex and hippocampus of APP/PS1 and APP/PS1 treated with N-AS mice (n = 8-9 mice per group). c-e Analysis of Aβ40 and Aβ42 depositions from the mice brain samples of the APP/PS1 and APP/PS1 treated with N-AS mice using immunofluorescence staining (c, d n = 7–9 mice per group) and ELISA kits (e n = 8 mice per group). f, g Quantification of amyloid angiopathy (f n = 8–9 mice per group, CAA) and tau hyperphosphorylation (g n = 6 mice per group, AT8) in cortex of APP/PS1 and APP/PS1 treated with N-AS mice. h Left, immunofluorescence images of microglia (Iba1) in cortex of WT, APP/PS1, and APP/PS1 treated with N-AS mice brain. Scale bars, 100 µm. Right, quantification of Iba1+ microglia in WT, APP/PS1, and APP/PS1 treated with N-AS (n = 9 mice per group). i Left, immunofluorescence images of astrocyte (GFAP) in cortex of WT, APP/PS1, and APP/PS1 treated with N-AS mice brain. Scale bars, 100 µm. Right, quantification of GFAP+ astrocyte in WT, APP/PS1, and APP/PS1 treated with N-AS (n = 8 mice per group). j mRNA levels of inflammatory markers in cortex of WT, APP/PS1, and APP/PS1 treated with N-AS mice brain (n = 4–6 per group). Pro-inflammatory marker: TNF-α, IL-1β, IL-6, and iNOS, Immuneinflammatory cytokine: IL-10. Anti-inflammatory marker: IL-4, TGF-β, and Arg1. k Learning and memory was assessed by Morris water maze test in the WT (n = 10), APP/PS1 (n = 14), and APP/PS1 injected with N-AS (n = 16) mice. l-o At probe trial day 11 of Morris water maze test, time spent in target platform (l) and other quadrants (m) was measured. Path length (n) and swim speed (o) analyzed. p The number of times each animal entered the small target zone during the 60 s probe trial. q Representative swimming paths at day 10 of training. a-g, i Student’s t-test. h, k, m-p One-way analysis of variance, Tukey’s post hoc test. All error bars indicate s.e.m. Source data are provided as a Source data file.
**Mutagenesis of the SphK1 and COX2 proteins.** Single point mutations in SphK1 (R56A, R57A, R24A, R185A, D178A, and F192A) and COX2 (S565A, N181A, T564A, and S567A) were generated using the In-Fusion Cloning Kits (Clontech) and ORF cDNA expression plasmids of human SphK1 and COX2 gene (Sino Biological Inc, HG15679-NH and HG12036-NH), according to the manufacturer’s instructions. The forward and reverse primers described in Supplementary Table 4.

**Enzyme kinetics.** The acetyl-CoA binding activity of SphK1 or the SphK1 WT and SphK1 mutants (R56A, R57A, R24A, and R185A) in the presence of ATP was analyzed by filter binding assay11. Briefly, SphK1 WT and mutant enzymes (1 μM) were resuspended in 100 μl reaction buffer (20 mM HEPES; pH 7.4, 50 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 0.02% Triton-X100, and 100 μM phosphoglycerol, all from Sigma-Aldrich). Reactions were initiated by adding [3H] acetyl-CoA (1–200 μM, 1.0–20 μCi, Perkin-Elmer, NET29005UC) and incubated at 37 °C for 1 h. The reactions were terminated by adding 100 μl of ice-cold reaction buffer containing 5 mM cold acetyl-CoA and immediately filtered through a 0.45 μM PTFE filter (Perkin-Elmer), followed by five washes. The N-AS binding activity of COX2 WT and COX2 mutants (S565A, N181A, T564A, and S567A) was analyzed similarly to the acetyl-CoA binding activity of SphK1. Briefly, COX2 WT and mutant enzymes (1 μM) were resuspended in 100 μl reaction buffer (20 mM HEPES; pH 7.4, 50 mM NaCl, 10 mM MgCl2, 1 mM EDTA, and 0.02% Triton-X100, all from Sigma-Aldrich). Reactions were initiated by adding [14C] N-AS (1–200 μM, 0.1–20 μCi, ARC UK Ltd, ARC-1024) and incubated at 37 °C for 1 h. The reactions were terminated by adding 100 μl of ice-cold reaction buffer containing 5 mM cold N-AS and immediately filtered through a 0.45 μM PTFE filter (Perkin-Elmer), followed by five washes.

**In vitro and in vivo acetylation assays.** Acetylation assays were performed according to previously described procedures with minor modifications11. To confirm the SphK1-mediated COX2 acetylation, 10 μg COX2 (LSBio, LS-G21094 and Cayman, 601122) was incubated with [14C] acetyl-CoA (2 μCi, Perkin-Elmer, NEC990005–1(5C)) and SphK1 (WT or mutants) in the presence of 100 μM NBD-sphingosine (100 μM, Sigma-Aldrich, S7049) and/or ATP (0–1000 μM, Amresco, 0220) at 37 °C for 2 h. To confirm N-AS mediated COX2 acetylation, 10 μg COX2 WT (WT or mutants) was used incubated with [14C] N-AS (2 μCi, ARC UK Ltd, ARC-1024) at 37 °C for 2 h. [14C] Asp (2 μCi, ARC UK Ltd, ARC-0473) was conducted as the positive control. The reactions were terminated by placing the reaction tubes in ice for 5 min. To evaluate in vivo neuronal and microglial COX2 acetylation, 10 μCi [14C] N-AS was orally administered to 9-months-old WT and APP/PS1 mice. After 1 h, neuron and microglia were isolated and sonicated in culture media. To immunoprecipitate acetylated COX2, the sample was incubated with COX2 antibody (Abcam, ab15191) at 4 °C for 24 h and precipitated by adding 50 μl of protein-A sepharose (GE Healthcare). Acetylated COX2 proteins bound to the beads were analyzed using a Triple Q-TOF TRAP liquid scintillation counter (Perkin-Elmer).

**General chemical synthesis.** All the reactions were carried out in oven dried glassware under nitrogen atmosphere with freshly distilled dry solvents under anaerobic conditions unless otherwise indicated. Flash column chromatography was performed with Silica Flash P60 silica gel (230–400 mesh). All reagents were obtained from commercial sources and were used without further purification. Proton (1H) and carbon (13C) NMR spectra were recorded on a 400/100 MHz Agilent 400 M FT-NMR spectrometer or 400/100 MHz Bruker Advance III 4D FT-NMR spectrometer. NMR solvents were obtained from Cambridge Isotope Laboratories and the residual solvent signals were taken as the reference (CDCl3, 7.26 ppm or DMSO-d6, 2.50 ppm for 1H NMR spectra and CDCl3, 77.0 ppm or DMSO-d6, 39.52 ppm for 13C NMR spectra). For annotated NMR spectra see Data. Mass analysis were carried out using Advion Expression CMS mass spectrometer and LC-ELSD analysis was carried out using Agilent 1260 Infinity ELSD coupled with Agilent 1220 HPLC. High resolution mass analysis was performed with JOEL AccuTOF 4G-DART-HRMS.

**Synthesis of acetyl sphingosines.** (S)–3-Hydroxy-1-methoxy-1-oxopropan-2-aminon chloride (1a)

To a solution of 1-Serine (530 mg, 5 mmol) in methanol (5 ml) at 0 °C was added SOC13 (1.27 ml, 17.5 mmol) dropwise. The mixture was stirred for overnight at 60 °C and concentrated in vacuo. The crude material was washed with ethanol (2 ml) to yield 1a (775 mg, 4.38 mmol) as a white solid.

1H NMR (400 MHz, DMSO-d6): δ 8.53 (br, 3H), 5.61 (t, J = 5.1 Hz, 1H), 4.11 (t, J = 3.6 Hz, 1H), 3.87–3.77 (m, 2H), 3.74 (s, 3H).

13C NMR (100 MHz, DMSO-d6): δ 168.47, 59.45, 54.42, 52.75. MS (APCI, M+H+): m/z found 120.0.

Methyl (tert-butoxycarbonyl)-1-serinate (1b)

To a solution of 1a (770 mg, 4.95 mmol) in DCM (16 ml) at 0 °C was added triethylamine (1.73 ml, 12.38 mmol) and BocO (1.42 g, 6.44 mmol). The mixture was slowly warmed to room temperature (RT), and stirred overnight. The mixture was concentrated in vacuo and purified by flash chromatography (10–30% ethyl acetate in hexanes) to yield 1b (997 mg, 4.55 mmol) as a yellow oil.

1H NMR (400 MHz, CDCl3): δ 5.42 (br s, 1H), 4.40 (br s, 1H), 4.00–3.88 (m, 3H), 3.79 (s, 3H), 2.19 (br s, 1H), 1.46 (s, 9H).

13C NMR (100 MHz, CDCl3): δ 171.33, 155.72, 80.29, 63.48, 55.69, 52.59, 28.26. MS (APCI, M+H+): m/z found 220.0.

3-(tert-Butyl)-4-methyl (S)-2,2-dimethyloxazolidine-3,4-dicarboxylate (1c)

To a solution of 1a (965 mg, 4.40 mmol) in toluene (11 ml) at RT was added p-toluenesulfonyl acid monohydrate (17 mg, 0.088 mmol), and 2,2-dimethoxypropane (1.1 ml, 8.85 mmol). The mixture was stirred for 2 h at 80 °C, and cooled to RT. The mixture was concentrated in vacuo, and purified by flash chromatography (5–15% ethyl acetate in hexanes) to yield 1c (692 mg, 2.67 mmol) as clear oil.

1H NMR (400 MHz, CDCl3): (as rotamers) δ 4.49 and 4.38 (2dd, J = 6.8, 2.8 Hz, and J = 7.0, 3.1 Hz, 1H), 4.17–4.11 (m, 1H), 4.07–4.01 (m, 1H), 3.76 (t, 3H), 1.41 (m, 15H).

13C NMR (100 MHz, CDCl3): (as rotamers) δ 171.66, 171.25, 152.07, 151.17, 95.04, 94.39, 80.86, 80.29, 66.24, 65.99, 59.26, 55.19, 52.36, 52.24, 28.33, 28.26, 26.00, 25.16, 24.93, 24.36.

MS (APCI, M+H+): m/z found 260.1.

tert-Butyl (R)-4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate (1d)

To a solution of lithium aluminum hydride (221 mg, 5.82 mmol) in THF (5 ml) at –78 °C was added a solution of 1c (500 mg, 1.92 mmol) in THF (5 ml) dropwise. The mixture was stirred for 10 min at –78 °C and warmed to RT, stirred for 30 min. The reaction was quenched by adding 1 N NaOH (10 ml) at –78 °C. The mixture was filtered through celite, and extracted with ethyl acetate. The organic layer was washed with Na2SO4, filtered and concentrated. The crude material was purified by flash chromatography (20–50% ethyl acetate in hexanes) to yield 1d (407 mg, 1.76 mmol) as a clear oil.

...
To a solution of DMSO (355 μl, 4.93 mmol) in DCM (0.5 ml) at –78 °C was added a solution of oxalyl chloride (215 μl, 2.47 mmol) in DCM (3.5 ml) dropwise. The mixture was stirred for 20 min, and was added DIPEA (1.75 ml, 10.5 mmol) as a yellow oil. The residue was filtered through celite, and concentrated in vacuo. The crude material was purified by flash chromatography (5–30% ethyl acetate in hexanes) to yield 1f (312 mg, 0.78 mmol) as a white solid.

1H NMR (400 MHz, CDCl3): δ 7.0, 3H). 13C NMR (100 MHz, CDCl3): 31.89, 29.66, 29.63, 29.62, 29.50, 29.32, 28.89, 28.51, 28.33, 22.66, 18.73, 14.09.

MS (APCI, M+H+): m/z found 442.3.

(2S,3R,E)-1-Acetoxy-3-hydroxyoctadec-4-en-2-aminium trihydroxide (1g)

To a solution of 1f (40 mg, 0.07 mmol) as a white solid in THF (0.1 ml) at 0 °C was added triethylsilane (15 μl, 0.11 mmol) in DCM (0.6 ml) dropwise. The mixture was stirred for 2 h, and was concentrated in vacuo. The crude material was purified by flash chromatography (5–15% ethyl acetate in hexanes) to yield 2a (31 mg, 0.07 mmol) as a white solid.

1H NMR (400 MHz, CDCl3): δ 5.79–5.71 (m, 1H), 5.49 (dd, J = 15.4, 6.8 Hz, 1H), 4.85 (br s, 1H), 4.27 (dd, J = 11.5, 6.2 Hz), 4.19–4.11 (m, 2H), 3.90 (br s, 1H), 2.35 (br s, 1H), 2.07 (s, 3H), 2.06–2.01 (m, 2H, 1.45 (s, 9H), 1.39–1.13 (m, 22H), 0.88 (t, J = 7.0, 3H).

13C NMR (100 MHz, CDCl3): δ 171.04, 155.84, 134.61, 128.26, 79.77, 73.18, 63.24, 54.01, 32.28, 31.29, 29.65, 29.63, 29.57, 29.47, 29.34, 29.20, 29.06, 28.31, 22.66, 20.86, 14.09.

MS (APCI, M+H+): m/z found 442.3.

(2S,3R,E)-1-Acetoxy-3-hydroxyoctadec-4-en-2-aminium trifluoroacetate (1-O-AS)

To a solution of 1g (400 mg, 1 mmol) in DCM (1.4 ml) at 0 °C was added acetic anhydride (10.4 μl, 0.11 mmol) in DCM (0.6 ml) dropwise. The mixture was stirred for 2 h, and was concentrated in vacuo to yield 1h (370 mg, 1.61 mmol) as a yellow oil. The residue was used in the next step without further purification.

tert-Butyl (S)-1,3-dihydroxyoctadec-4-yn-2-yl)carbamate (1f)

To a solution of 1f (312 mg, 0.78 mmol) as a white solid in DCM (0.5 ml) at –78 °C was added n-butyllithium (0.5 ml, 1 mmol, 2 M in hexanes) dropwise. The mixture was cooled to 0 °C, and was added 1N HCl (0.3 ml) dropwise. The mixture was stirred for 2 h, and slowly warmed to RT, and was stirred for 6 h. The mixture was cooled to 0 °C, and was added 1 N HCl (0.3 ml) dropwise. The mixture was filtered through celite, and concentrated in vacuo. The crude material was purified by flash chromatography (5–30% ethyl acetate in hexanes) to yield 1f (370 mg, 1.61 mmol) as a yellow oil. The residue was used in the next step without further purification.

tert-Butyl (S)-4-formyl-2,2-dimethoxazolidine-3-carboxylate (1e)

To a solution of DMSO (355 μl, 4.93 mmol) in DCM (0.5 ml) at –78 °C was added n-butyl lithium (0.5 ml, 1 mmol, 2 M in hexanes) dropwise. The mixture was stirred for 20 min. The mixture was warmed to RT, and was stirred for 19 h. The mixture was concentrated in vacuo, and the crude material was purified by flash chromatography (20–50% ethyl acetate in hexanes) to yield 1g (952 mg, 2.39 mmol) as a white solid.

1H NMR (400 MHz, CDCl3): δ 3.91 (br s, 1H), 2.19 (td, J = 7.1, 1.8 Hz, 2H), 1.52–1.24 (m, 37H), 0.88 (t, J = 7.0, 3H).

13C NMR (100 MHz, CDCl3): δ 7.0, 3H). 13C NMR (100 MHz, CDCl3): δ 11.5, 6.2 Hz, 1H), 4.19 (s, 9H), 2.01 (m, 2H) 1.45 (s, 9H), 1.39–1.13 (m, 22H), 0.88 (t, J = 7.0, 3H).

13C NMR (100 MHz, CDCl3): δ 171.65, 137.13, 124.65, 79.77, 73.18, 63.24, 54.01, 32.28, 31.29, 29.65, 29.63, 29.57, 29.47, 29.34, 29.20, 29.06, 28.31, 22.66, 20.86, 14.09.

MS (APCI, M+H+): m/z found 442.3.

(2S,3R,E)-1-Acetoxy-3-hydroxyoctadec-4-en-2-aminium trifluoroacetate (1-O-AS)
To a solution of 1h (37 mg, 0.092 mmol) and imidazole (12.5 mg, 0.184 mmol) in DCM (0.6 ml) at 0 °C was added a solution of tert-butyldimethylsilyl chloride (10.15, 0.11 mmol) as a pale-yellow oil. To a solution of tert-butyldimethylsilyl chloride (6.6 mg) to a solution of pyridine (10 ml) in DCM (0.7 ml) at RT, was added acetic anhydride (10.5 mmol). The mixture was stirred for 1 h, and slowly warmed to 50 °C over 1 h, and stirred for 18 h. The crude material was purified by flash chromatography (5–10% ethyl acetate in hexanes) to yield 3b (38 mg, 0.068 mmol) as a clear oil.

1H NMR (400 MHz, CDCl3): δ 5.81–5.73 (m, 1H), 5.41 (dd, J = 15.4, 7.6, 1H), 5.27 (t, J = 7.2 Hz, 1H), 4.71 (br d, J = 8.9 Hz, 1H), 3.85 (br s, 3H), 3.70 (dd, J = 10.1, 3.5 Hz, 1H), 3.60 (dd, J = 10.2, 4.5 Hz, 1H), 2.05–1.98 (m, 5H), 1.44 (s, 9H), 1.38–1.22 (m, 22H), 0.90–0.86 (m, 12H), 0.04 (s, 6H).

13C NMR (100 MHz, CDCl3): δ 169.71, 155.41, 136.77, 124.74, 79.29, 74.68, 73.78, 61.79, 53.70, 32.34, 31.91, 29.67, 29.65, 29.59, 29.47, 29.35, 29.22, 28.89, 28.36, 25.82, 22.68, 21.25, 18.11, 14.11, –5.57, –5.59.

MS (APCI, M+H+: m/z found 514.4, 515.4, 516.4, 517.4, 518.4).

Synthesis of N-AS from 1-O-AS
To a solution of 1-O-AS (13.5 mg, 0.029 mmol) in DCM (0.53 ml) at RT, was added triethylamine (90 µl, 0.64 mmol), and was stirred for 3 h. The mixture was concentrated in vacuo, and purified by flash chromatography (5–10% methanol in DCM) to yield N-AS (9 mg, 0.026 mmol) as a white solid.

Synthesis of N-AS from 3-O-AS
To a solution of 3-O-AS (17 mg, 0.037 mmol) in DCM (0.6 ml) at RT, was added triethylamine (115 µl, 0.82 mmol) and was stirred for 3 h. The mixture was concentrated in vacuo, and purified by flash chromatography (5–10% methanol in DCM) to yield N-AS (10 mg, 0.029 mmol) as a white solid.

1H NMR (400 MHz, CDCl3): δ 6.63 (br d, J = 5.5 Hz, 1H), 5.83–5.75 (m, 1H), 5.53 (dd, J = 15.4–6.4 Hz, 1H), 4.35–4.31 (m, 1H), 3.99–3.98 (m, 2H), 3.71 (dd, J = 11.0, 3.1 Hz, 1H), 2.09–2.02 (m, 5H), 1.40–1.22 (m, 22H), 0.88 (s, J = 7.0, 3H).

13C NMR (100 MHz, CDCl3): δ 171.09, 134.18, 128.59, 74.24, 62.12, 54.56, 32.28, 31.90, 29.66, 29.63, 29.61, 29.48, 29.33, 29.22, 23.51, 22.31, 14.09.

HRMS (DART, M+H+: m/z calcd for C20H40NO3 342.3034, found 342.3002, 342.3031).

LC-ELSD analysis. To a solution of 1-O-AS (0.25 mg) or 3-O-AS (0.25 mg) in water (400 µl) and DMSO (50 µl) at RT was added sodium phosphate buffer (pH 7.4, 0.1 M, 50 µl). The solution was mixed homogeneously with micropipette and was incubated at 25 °C for 10 min. Reverse-phase HPLC was performed using Agilent 1220 coupled with Agilent 1260 Infinity ELSD. Phenomenex Kinetex 1.7 µm C8 100 A (50 × 21 mm LC column) at a flow rate of 0.5 ml min⁻¹ was used. A gradient of acetonitrile with 0.1% formic acid was used as an eluent.

LC-MS/MS analysis for structure elucidation of N-AS. To determine whether N-AS was synthesized by acetyl-CoA and sphingosine within SphK1, 10 mM acetyl-CoA (Sigma-Aldrich, A2056) and 100 µM sphingosine (Sigma-Aldrich, S7049) were incubated with purified SphK1 (Cayman, 10348) at 37 °C for 24 h in acetylation buffer (50 mM Tris-HCl pH 7.6, 1 mM DTT, 1 mM EDTA, and 10% glycerol, all from Sigma-Aldrich). Also, SphK1 WT, SphK1 D178A, and SphK1 F192A were incubated with 100 µM sphingosine and acetyl-CoA ranging from 0 to 10 mM. Reactions were quenched by adding equal volume of cold methanol. A 100 µl aliquot of the reaction mixture was mixed with 30 µl of distilled water containing 5 mg ml⁻¹ of fosfomide (internal standard) for 1 min and vigorously mixed with 0.7 ml of ethyl acetate for 20 min. After centrifugation at 16,000×g for 10 min, the mixtures were kept for 2 h for freezing aqueous phase. The upper ethyl acetate layer was transferred to a clean tube and evaporated to dryness under gentle stream of nitrogen. Then, the dried extract was reconstituted in 100 µl of mobile phase and 10 µl aliquot of the solution was injected into an Agilent 6470 Triple Quad LC-MS/MS system (Agilent, Wilmington, DE) coupled with an Agilent 1260 Infinity ELSD. Separation was performed on a Synergy Polar RP column (4 mm particle size, 2.0 mm × 150 mm, Phenomenex) using a mobile phase that consisted of methanol and water (95:5, v/v) with 0.1% formic acid at a flow rate of 0.2 ml min⁻¹. Quantification was carried out using multiple reaction monitoring (MRM) at m/z 342.3→263.3 for N-AS (m/z 329.8→284.8 for fosfomide (internal standard) in negative ionization mode and collision energy of 20 eV. The lower limit of quantification was determined to be 0.5 ng ml⁻¹ and linearity was observed in the standard range of 0.5–200 ng ml⁻¹. Also, to confirm N-AS generation in neurons, microglia, and astrocytes, these cells were treated with Aβ, and sonicated in neuronal and glial culture medium. The supernatants were supplemented with acetyl-CoA (100 µM, Sigma-Aldrich, A2056), SphK1 (20 ng, Cayman, 10348), or sphingosine (1 µM, Sigma-Aldrich, S7049), and incubated at 37 °C for 2 h. To evaluate N-AS in microglia and neurons in vivo, the cells were isolated from WT mice, APP/PS1 mice and APP/PS1 mice treated with N-AS at 9 months of age. The cells were sonicated and resuspended in glial and neuronal culture medium, respectively. A 100 µl aliquot of each cell lysate were used for the determination of N-AS using a method previously described.
incubated with 1μg sequencing-grade modified porcine trypsin (Promega) in 0.1M ammonium bicarbonate buffer at 37°C for 16 h. The sample was then treated with 1M iodoacetamide (Sigma-Aldrich) for 1 h. For sequencing, the protein samples were loaded onto a ZORBAX 300SB-C18 column (3.5 μm, 1.0 mm i.d. × 150 mm, Agilent). The column was placed in-line with an Ultimate 3000 system (Dionex, USA) and a splitter system was used to achieve a flow rate of 100μl/min. Analytes were eluted with a mobile phase consisting of water/formic acid (100:0.2 v/v) (phase A) and acetonitrile:formic acid (100:0.2 v/v) (phase B) in gradient elution mode for 77 min. Eluted peptides were directly electrosprayed into and MicroQ-TOF III mass spectrometer (Bruker Daltonics, 255748, Germany) by applying 4.5 kV of capillary voltage and a normalized collision energy of 7 eV. The peptides were verified with BioTools 3.2 SR5 (Bruker Daltonics).

Peptide and antibodies generation. Polyclonal and monoclonal anti-acetyl COX2 S565 antibodies were generated using the COX2 peptide including acetylated S565 residue to immunize rabbits and mice (GenScript). Double affinity purification was performed using native and acetylated peptides sequentially using SulfoLink columns (Thermo Fisher Scientific).

Biosynthesis and lipid mediators metabololipidomics. Lipid mediators metabololipidomics were performed according to previously described procedures with minor modifications29. To confirm the biosynthesis of lipid mediators by recombinant COX2 treatment, we used N-AS (9-months-old) or APP/PS1 (3, 5, 9 months-old), APP/PS1 treated with N-AS (9-months-old) or APP/PS1 treated with aspirin (9-months-old) mice were minced in Hibernate A (Gibco)/B27 (Invitrogen) medium and incubated with N-AS (2.5 μg, 2 h, Sigma-Aldrich, 01912), and were analyzed for the generation and roles of N-AS.

Cell isolation. Adult neurons and microglia were isolated from the mice brain as previously described31. In brief, the cortex of WT (1, 3, 5, or 9-months-old), APP/PS1 (3, 5, 9 months-old), APP/PS1 treated with N-AS (9-months-old) or APP/PS1 treated with aspirin (9-months-old) mice were minced in Hibernate A (Gibco)/B27 (Invitrogen) medium and dissociated using papain (Worthington) solution. After tissue trituration, cells were separated by Optiprep (Sigma-Aldrich) density gradient centrifugation. Microglia were plated with microglia-specific medium (DMEM/F12 containing 10% FBS and 1% penicillin-streptomycin). The immortalized human microglia (Applied Biologics Materials, T0251) were cultured in Prigrow III (Applied Biologics Materials, TM003) (supplemented with 10% FBS and 1% penicillin-streptomycin) at 37°C in a humidified atmosphere of 5% CO2. In order to assess the clinical importance of N-AS in AD microglia, Aβ 1–42 (50 μM, 24 h, Invitrogen, 03112) was exposed to human microglia before treated with zileuton (50 μM, 24 h, Sigma-Aldrich, Z2477). The human microglia treated with Aβ 1–42 and/or zileuton was incubated with N-AS (2.5 μg, 2 h, Sigma-Aldrich, 01912), and were analyzed for the generation and roles of N-AS. Western blotting. Samples were lysed in RIPA buffer (Cell signaling Technologies), then subjected to SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blocked with 5% milk, incubated with primary antibody and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody33. Primary antibodies to the following proteins were used: ac-SNAP25 (rabbit, 1:1,000 and mouse, 1:200, Millipore, MAB377) and microgal (Iba1, rabbit, 1:1,000, Wako, 019-19941) markers and the isolated neurons and microglia were acutely analyzed for the acetylation assay and lipid mediators metabololipidomics.

Histochemical analysis. Thiolfavin S (Sigma-Aldrich) staining was carried out according to previously described procedures34. We used 6E10 (mouse, 1:100, Signet, SG93000), anti-B27 (mouse, 1:1000, provided by D. R. Howlett, GlaxoSmithKline, Harlow, Essex, UK) for Aβ42, anti-g30 (rabbit, 1:1000, provided by D. R. Howlett) for Aβ40, SMA (mouse, 1:400, Sigma-Aldrich, A2547), AT8 (mouse, 1:500, Thermo Fisher Scientific, MN1020), Caspase-3, mouse, 1:200, Novus Biologicals, NB100-56708) and COX2 (mouse, 1:250, Thermo Fisher Scientific, TS5270), Iba1 (rabbit, 1:500, Wako, 019-19941) and goat, Abcam, ab5076), NeuN (rabbit, 1:500, Millipore, MAB177), GFAP (rabbit, 1:500, Dako, N1506 and chicken, 1:500, Abcam, ab6476), and Lamp1, mouse, 1:200, Abcam, ab24170). The sections were analyzed with a laser-scanning confocal microscope (FV3000; Olympus) or with a BX51 microscope (Olympus). Meta-Morph software (Molecular Devices) was used to quantify. Three-dimensional reconstruction of microglia was recorded and analyzed using IMARIS software (Bitplane)35. For the analysis of age-dependent microglial COX2 activity, co3xcr1+ cells in WT and APP/PS1 mice, COX2 (rabbit, 1:1,000, Abcam, ab15191) and C3XR1 (mouse, 1:100, BioLegend, 149008) antibody were used and the images were acquired on Alexa 488 and APC Channel with performed using ImagePro Plus software. Images have been cropped for presentation.

Lipid extraction and sphingosine quantification. To quantify the sphingosine levels, the dried lipid extract was resuspended in 0.2% Igepal CA-630. Four microliters of the lipid extracts was added into 20 μl of NDA derivatization reaction mixture (25 mM borate buffer, pH 9.0, containing 2.5 mM each of NDA and NaCN). The reaction mixture was diluted 1:3 with ethanol, incubated at 50°C for 10 min and centrifuged at 15,493×g for 5 min. A 30 μl aliquot of the supernatant was then transferred to a sampling glass vial and 5 μl was applied onto a UPLC system for analysis. The fluorescent sphingosine was monitored using a model 474 scanning fluorescence detector (Waters). Quantification of the sphingosine was carried out from sphingosine calibration curves using the Waters Millennium software.

ELISA. For measurement of acetyl-COA in neurons and microglia, we used commercially available ELISA kits (Abcam, ab87546) according to the manufacturer’s
instructions. For measurement of Aβ40 and Aβ42, we used commercially available ELISA kits (Invitrogen, KHB3481, and KHB3441). Cortex of mice was homogenized in buffer containing 0.2% MgCl₂. ELISA was then performed for Aβ40 and Aβ42 according to the manufacturer’s instructions.

Microsomal stability. An N-AS stock solution (10 mM dissolved in methanol) was diluted with methanol to make a concentration of 100 μM. A 10 μl aliquot of this solution was then diluted using 90 μl of 100 mM potassium phosphate buffer (pH 7.4). 10 μl of this N-AS solution was incubated at 37 °C with human or mouse liver microsomes (80 μl of 0.625 mg protein ml⁻¹ phosphate buffer) for 10 min before adding 10 μl of an NADPH regenerating system to start the reaction. Reactions were stopped at 0, 15, 30, 60, and 90 min-time points by the addition of 200 μl cold acetonitrile (containing propranolol as internal standard at 20 ng ml⁻¹) and centrifuged at 17,968×g for 10 min. A 2 μl aliquot of the supernatant was injected into the LC-MS/MS system. The ratio of peak area of test compound/internal standard was used to determine the % remaining of N-AS over time. The half-life (T1/2) and % compound remaining after 30 min were then calculated.

Cytochrome P450 inhibition. N-AS stock solution (10 mM dissolved in methanol) was serially diluted with methanol to make concentrations of 100, 250, 500, 2,500, and 10,000 μM. A 10 μl aliquot of this solution was then diluted using 90 μl of 100 mM potassium phosphate buffer (pH 7.4). Probe substrate cocktail solutions for seven major cytochrome P450 isozymes (phenacetin (100 μM for 1A2), bupropion (50 μM for 2B6), diclofenac (20 μM for 2C9), mephenytoin (100 μM for 2C19), dextromethorphan (5 μM for 2D6), chlorozoxazone (50 μM for 2E1), and midazolam (5 μM for 3A4)) were prepared with phosphate buffer. A 10 μl aliquot of N-AS solution and a 10 μl aliquot of each probe substrate cocktail solution was incubated at 37 °C with human liver microsomes (80 μl of 0.625 mg protein ml⁻¹ phosphate buffer) for 10 min before the addition of 10 μl of the NADPH regenerating system to start the reaction. Reactions were stopped at 15 min by the addition of 200 μl cold acetonitrile (containing propranolol as internal standard at 20 ng ml⁻¹) and centrifuged at 17,968×g for 10 min. A 2 μl aliquot of the supernatant was injected into the LC-MS/MS system. The ratio of peak area of test compound/internal standard was used to determine the % metabolic activity of probe substrate according to the concentrations of N-AS added.

PK and brain distribution of N-AS. C57BL/6 mice were administered N-AS (Sigma-Aldrich, 01912) at doses of 1 mg kg⁻¹ (p.o.), 10 mg kg⁻¹ (p.o.), Venous blood samples were collected at 5, 15, and 30 min, and 1, 2, 4, 8, and 24 h postdose. A 30 μl of plasma was separated from whole blood by centrifugation and stored at −80 °C until analysis. Also, brain samples were collected at 1, 2, 4, and 24 h postdose and heart, liver, and kidney samples were collected at 24 h postdose, thoroughly rinsed with physiological saline and weighed. Twenty percentage of tissue homogenates were prepared by homogenizing the tissue samples with four volumes of saline. A 30 μl aliquot of plasma or a 50 μl aliquot of tissue homogenates were deproteinized by addition of 200 μl cold methanol (containing naringenin as internal standard at 20 ng ml⁻¹) and centrifuged at 15,974×g for 10 min. A 10 μl aliquot of the supernatant was injected into the Agilent 6470 UPLC/MS/MS system. Separation was performed on a Synergy Polar RP column (4 μm particle size, 2.0 mm ×150 mm, Phenomenex) using a mobile phase that consisted of methanol and water (85:15, v/v) with 0.1% formic acid at a flow rate of 0.2 ml min⁻¹. Quantification was carried out using multiple reaction monitoring (MRM) with the following pairs of transitions: 347.1→151.3 for N-AS and 151.3→151.3 for naringenin (internal standard) in negative ionization mode and collision energy of 20 eV. p and relative oral BA values were calculated as follows: BA% = AUCp,AUCr normalized by p.o. dose/AUCv normalized by i.v. dose × 100.

Mice. Transgenic mouse lines over-expressing the hAPP695sws (APP) and presenilin-1M146V (PS1) mutations were originated from GlaxoSmithKline (Harlow, UK)⁴ and maintained as described previously⁴. We purchased 5×FAD presenilin-1M146V (PS1) mutations were originated from GlaxoSmithKline (Gibco) for 8 weeks. Also, to confirm possible therapeutic effect of N-AS and aspirin in APP/PS1 mice, the N-AS (30 mg kg⁻¹, Sigma-Aldrich, 01912) was injected daily s.c. for 8 weeks to 7-months-old APP/PS1 mice until the age of 9 months, and aspirin (2 mg kg⁻¹, Sigma-Aldrich, A53761)⁴ was administered orally to 7-months-old APP/PS1 mice for 8 weeks. Also, to confirm possible therapeutic efficacy of N-AS in 5xFAD, the N-AS (30 mg kg⁻¹, Sigma-Aldrich, 01912) was injected daily s.c. for 4 weeks to 3-months-old 5xFAD mice until the age of 4 months. Block randomization method was used for allocation of experimental groups. To eliminate bias, we were blinded in experimental progress such as data collection and data analysis. Mice were housed at temperature of 22 °C and a 12 h day/12 h night cycle with free access to tap water and food pellets. All protocols were approved by the Kyungpook National University Institutional Animal Care and Use Committee.

Flow cytometry. Brain microglia polarity and immune cells in brain and blood were analyzed by flow cytometry. Cells from WT, APP/PS1, and APP/PS1 treated with N-AS mice brain were prepared as previously described with minor modifications²⁴.Brains of WT, APP/PS1, and APP/PS1 treated with N-AS mice were dissected and immediately transferred in ice-cold HBSS (Gibco). After gentle mincing, the brain was digested in a NOS solution containing collagenase A (0.3 mg ml⁻¹, Roche), dispase II (0.8 mg ml⁻¹, Roche), DNase I (0.01 mg ml⁻¹, Roche), and collagenase A (0.3 mg ml⁻¹, Roche) at 37 °C for 1 h under gentle rocking. Digestion was stopped by adding PBS (Gibco) on ice. The supernatants were centrifuged at 250 g for 10 min at 4 °C. The pellet was resuspended in 25% BSA (Gibco)/PBS (Gibco) for myelin removal. Following a centrifugation step at 3000 g for 30 min at 4 °C, the myelin containing supernatant was discarded. The cell pellets were then resuspended in 1 ml of HBSS and filtered through a 40 μm mesh, followed by a washing step in HBSS. The cell pellets were resuspended in 1 ml of red blood cell lysis buffer (BD Biosciences) and incubated at RT for 10 min for lysis of erythrocytes. Subsequently, 2 ml of MACs buffer (Miltenyl Biotec, 130-091-222) was added and centrifuged at 250 g for 10 min at 4 °C. Cells from WT, APP/PS1, and APP/PS1 treated with N-AS mice blood were prepared as previously described with minor modifications²⁵. Blood was collected in sodium-heparin tube (BD, 367871) by cardiac puncture. Red blood cells were lysed once at 4 °C in 0.15 M NH₄Cl (STEMCELL Technologies). Microsomes were prepared by p.o. dose/AUCi.v. normalized by i.v. dose × 100.

Phagocytosis assay. The phagocytic activity of adult microglia in the cortex of live brain slices was analyzed as following protocol²¹. Brains from WT, APP/PS1, and APP/PS1 mice treated with N-AS were washed in carbogen-saturated (95% O₂ and 5% CO₂) humidified carbogen (95% O₂ and 5% CO₂) containing (in mM) CaCl₂ 2.5; MgSO₄ 1.3; CaCl₂ 2.5; NaH₂PO₄ 1.25; NaHCO₃ 26; and D-glucose 10; pH 7.4. The brains were placed in a brain chamber mounted on a heated stage under a cover glass (purchased from MatTek, Ashland, MA) and held in a humidified carbogen (95% O₂ and 5% CO₂) containing (in mM) CaCl₂ 2.5; MgSO₄ 1.3; CaCl₂ 2.5; NaH₂PO₄ 1.25; NaHCO₃ 26; and D-glucose 10; pH 7.4 (all from Sigma-Aldrich). Coronal slices (130 μm) were prepared using a vibratome (Leica Biosystems) at 4 °C and allowed to rest in ACSF buffer at RT for 1 h before incubation with fluorescent carbosylated microspheres (1 μm diameter, Fluos- Spheres, Invitrogen, 1:2000) in PBS (Gibco) containing 4.5 μg/ml-1 eGFP (Sigma-Aldrich) at 37 °C for 1 h. The slices were washed and fixed with 4% PFA. Followed by donkey anti-rabbit Alexa 594 (1:1000, Invitrogen). The sections were analyzed with a laser-scanning confocal microscope (Nikon Eclipse TE2000-U). Meta Morph software (Molecular Devices) was used to quantification.

RNAseq. Total RNA was isolated in microglia derived from WT, APP/PS1, and APP/PS1 mice treated with Trizol reagent (Invitrogen). RNA quality was assessed by Agilent 2100 bioanalyzer using the RNA 6000 Nano Chip (Agilent Technologies, Amstelveen, The Netherlands), and RNA quantification was performed using ND-2000 Spectrophotometer (Thermo Inc., DE, USA). To prepare sequence libraries, libraries were prepared from 1 μg of total RNA using the SMARTer Stranded RNA-Seq Kit (Clontech Laboratories, Inc., USA). RNA data were acquired on a BAC FACSarray II flow cytometer (BD) using Diva software (BD) and further analyzed using FlowJo analytical software (Tree Star, Inc.).
RNA isolation and real-time PCR analysis. For total RNA extraction from the microglia derived from WT, APP/PS1, APP/PS1 mice treated with N-Ac, and APP/PS1 mice treated with N-Ac, or aspirin using the methods described above. Total RNA was isolated using the kit components according to the manufacturer’s instructions (RNeasy mini kit, 74134, qiagen). cDNA was synthesized from 5 μg of total RNA using a commercially available kit (Takara). Quantitative real-time PCR was performed using a Corbett research RG-6000 real-time PCR instrument. Primers are described in Supplementary Table 5.

Behavioral studies. We performed behavioral studies to assess spatial learning and memory in the Morris water maze as previously described[15,16]. Animals were given four trials per day for 10 days to learn the task. At day 11, animals were given a probe trial in which the platform was removed. Fear conditioning was conducted by previously described techniques[23]. On the conditioning day, mice were individually placed into the conditioning chamber. After a 60 s exploratory period, a tone (10 kHz, 70 dB) was delivered for 10 s; this served as the conditioned stimulus (CS). The CS co-terminated with the unconditioned stimulus (US), a scrambled electrical footshock (0.3 mA, 1 s). The CS-US pairing was delivered twice at a 20 s interval. On day 2, each mouse was placed in the fear-conditioning chamber containing the same exact context, but with no administration of a CS or foot shock. Freezing was analyzed for 5 min. On day 3, a mouse was placed in a test chamber that was different from the conditioning chamber. After a 60 s exploratory period, the tone was presented for 60 s without the footshock. The rate of freezing was analyzed for 5 min. On day 3, a mouse was placed in a test containing the same exact context, but with no administration of a CS or foot shock. Freezing was analyzed for 5 min. On day 3, a mouse was placed in a test chamber that was different from the conditioning chamber. After a 60 s exploratory period, the tone was presented for 60 s without the footshock. The rate of freezing was measured to model the fear memory. The open field test was used for locomotion and anxious behaviors as previously described. The open field test consisted of a square box. Each animal was placed in the box for 10 min. Overall activity in the box was measured, and the amount of time and distance traveled was recorded in the center arena was noted. After each trial, the test chambers were cleaned with a damp towel and distilled water followed by 70% alcohol. The light-dark test was used for assessing the anxiety-like behavior as previously described[23]. One chamber was brightly illuminated, whereas the other chamber was dark. Mice were placed into the dark chamber and allowed to move freely between the two chambers for 5 min for 2 h and analyzed using the ImageJ software (National Institutes of Health).

Live-cell phagocytosis assay. Live-cell phagocytosis assays were performed according to previously described procedures with minor modifications[26]. Briefly, in a glass bottom cell culture dish (SPL, 101350), adult SV40 immortalized human astrogloma cells were seeded at a density of 5 × 10^5 cells per well. The seeded cells were incubated with 0 or 50 μg/mL of FITC beads (Invitrogen) preopsonized in PBS (Gibco) were added at a concentration of 0.01% and then immediately observed using a laser scanning confocal microscope equipped with a live cell chamber system (VF3000, Olympus) for 2 h. Confocal images were collected every 5 min for 2 h and analyzed using the ImageJ software (National Institutes of Health).

Statistical analysis. Sample sizes were determined by G-Power software (with α = 0.05 and power of 0.8). In general, statistical methods were not used to calculate or predetermined sample sizes. Variance was similar within comparable experimental groups. Experimenters were blinded to the identity of experimental groups until the end of data collection and analysis for at least one of the independent experiments. Comparisons between two groups were performed with Student’s t-test. In cases where more than two groups were compared to each other, a one way analysis of variance (ANOVA) was used, followed by Tukey’s HSD test. All statistical analyses were performed using SPSS statistical software and GraphPad Prism 7.0 software. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 were considered to be significant.

Data availability

The datasets generated and/or analyzed during the current study are also available from the corresponding authors upon reasonable request. The source data underlying Figs.1a, b, 1c, 2a–i, 4b–d, 5a–i, 6a–d, 7a–h, 7j–m, 7o–q, and 8b–i are provided as a Source Data file. RNAseq data is deposited in the GEO database (GSE146133) https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE146133.

Received: 17 May 2019; Accepted: 9 April 2020; Published online: 12 May 2020

References

1. Alhouayek, M. & Muccioli, G. G. COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol. Sci. 35, 284–292 (2014).
2. Tosco, P. A mechanistic hypothesis for the aspirin-induced switch in lipid mediator production by cyclooxygenase-2. J. Am. Chem. Soc. 135, 10404–10410 (2013).
3. Serhan, C. N. et al. Novel functional sets of lipid-derived mediators with anti-inflammation actions generated from omega-3 fatty acids via cyclooxygenase-2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197–1204 (2000).
4. Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammatory signals. J. Exp. Med. 196, 1025–1037 (2002).
5. Sharma, N. P., Dong, L., Yuan, C., Noon, K. R. & Smith, W. L. Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids. Mol. Pharmacol. 77, 979–986 (2010).
6. Buckley, C. D., Gilroy, D. W. & Serhan, C. N. Resolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40, 315–327 (2014).
7. Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101 (2014).
8. Wang, X. et al. Resolution of inflammation is altered in Alzheimer’s disease. Alzheimers Dement. 11, 10–20 (2015).
9. Zhu, M. et al. Pro-resolving lipid mediators improve neuronal survival and increase Aβ42 phagocytosis. Mol. Neurobiol. 53, 2733–2749 (2016).
10. Wang, Z. et al. Molecular basis of sphingosine kinase 1 substrate recognition and contextual regulation of COX2 activity by FYN in prostate cancer cells. Oncotarget 5, 4232–4243 (2014).
11. Lan, X., Han, X., Li, Q., Yang, Q. W. & Wang, J. Modulators of microglial activation and polarization after intracerebral haemorrhage. Nat. Rev. Neuro. 13, 420–433 (2017).
12. Alexanian, A., Miller, B., Chesnik, M., Mirza, S. & Sorokin, A. Posttranslational regulation of COX2 activity by FYN in prostate cancer cells. Oncotarget 5, 4232–4243 (2014).
13. Schwartz, M. & Deczkowska, A. Neurological disease as a failure of brain–immune crosstalk: the multiple faces of neuroinflammation. Trends Immunol. 36, 668–678 (2016).
14. Jung, J. S., Ahn, Y. H., Moon, B. I. & Kim, H. S. Exogenous C2 ceramide suppresses matrix metalloproteinase gene expression by inhibiting ROS production and MAPK signaling pathways in PMA-stimulated human astrogloma cells. Int. J. Mol. Sci. 17, 497 (2016).
15. Zha, W., Wang, X., Zhou, Y. & Wang, H. C2-ceramide induces cell death and protective autophagy in head and neck squamous cell carcinoma cells. Int. J. Mol. Sci. 15, 3336–3354 (2014).
16. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005–1015 (2006).
17. Lin, M. T. & Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787–795 (2006).
18. Ronowska, A. et al. The regulatory effects of acetyl-CoA distribution in the healthy and diseased brain. Front. Cell Neurosci. 12, 169 (2018).
19. Salter, M. W. & Stevens, B. Microglia emerge as central players in brain inflammatory drugs and transcellular signals. J. Exp. Med. 215, 3240–3249 (2017).
20. Johansson, J. U. et al. Prostaglandin signaling suppresses beneficial microglial response in Alzheimer’s disease mouse models. J. Clin. Invest. 125, 350–364 (2015).
21. Shi, Y. & Holtzman, D. M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 18, 759–772 (2018).
22. Nakagawa, Y. & Chiba, K. Role of microglial m1/m2 polarization in relapse and remission of psychiatric disorders and diseases. Pharmaceuticals 7, 1028–1048 (2014).
23. Rossi, A. et al. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. Br. J. Pharm. 161, 555–570 (2010).
24. Cuello, A. C. Early and late CNS inflammation in Alzheimer’s disease: two scenarios of a continuum? Trends Pharmacol. Sci. 38, 956–966 (2017).
25. Salter, M. W. & Stevens, B. Microglia emerge as central players in brain disease. Nat. Med. 23, 1018–1027 (2017).
30. Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R. & Serhan, C. N. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569–581 (2011).
31. Lee, J. K. et al. Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer’s disease. J. Exp. Med. 211, 1551–1570 (2014).
32. Howlett, D. R. et al. Cognitive correlates of Abeta deposition in male and female, K/amp phosphorylation, amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 1017, 130–136 (2004).
33. Chandra, S., Jana, M. & Pahan, K. Aspirin induces lysosomal biogenesis and attenuates amyloid plaque pathology in a mouse model of Alzheimer’s disease via PPARα. J. Neurosci. 38, 6682–6699 (2018).
34. Scholz, A. et al. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol. Med. 8, 39–57 (2016).
35. Park, M. H. et al. Neuropeptide Y induces hematopoietic stem/progenitor cell mobilization by regulating matrix metalloproteinase-9 activity through Y1 receptor in osteoblasts. Stem Cells 34, 2145–2156 (2016).
36. Hu, X. et al. Microglial and macrophage polarization—new prospects for brain repair. Nat. Rev. Neurosci. 11, 56–64 (2015).
37. Zhou, T. et al. Microglia polarization with M1/M2 phenotype changes in rd1 mouse model of retinal degeneration. Front. Neuroanat. 11, 77 (2017).
38. Aryal, B. et al. ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression. Nat. Commun. 7, 12313 (2016).
39. Möhle, I. et al. Lys6C(h)i monocytes provide a link between antibiotic-induced changes in gut microbiota and adult hippocampal neurogenesis. Cell Rep. 15, 1945–1956 (2016).
40. Zenaro, E. et al. Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via LFA-1 integrin. Nat. Med. 21, 880–886 (2015).
41. Yang, K., Neale, G., Green, D. R., He, W. & Chi, H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat. Immunol. 12, 888–897 (2011).
42. Knier, B. et al. Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity. Nat. Immunol. 19, 1341–1351 (2018).
43. Nakao, A. et al. Comprehensive behavioral analysis of voltage-gated calcium channel beta-anchoring and -regulatory protein knockout mice. Front. Behav. Neurosci. 9, 141 (2015).
44. Lucin, K. M. et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer’s disease. Neuron 79, 873–886 (2013).

Acknowledgements
This research was supported by the Basic Science Research Program (2017R1A1A1015652, 2020R1A2C3006875) and the Original Technology Research Program for Brain Science (2018M3C7A1056513) of the NRF funded by the Korean government, MSIT. This research was also supported by a grant of the Korea Health Technology R&D Project through the KHIDI, funded by the Ministry of Health & Welfare, Republic of Korea (HI16C2131) and Research Fund (1.180002.01) of UNIST.

Author contributions
J.Y.L. and S.H.H. designed and performed experiments and wrote the paper. M.H.P., I.S., and M.K.C. performed LC-MS/MS experiments and analyzed data. E.Y. and C.M.P. synthesized and provided ASs. I.S.S., C.M.P., H.J.K., S.H.K., E.H.S., H.K.J., and J.S.B. interpreted the data and reviewed the paper. H.K.J. and J.S.B. designed the study and wrote the paper. All authors discussed results and commented on the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-020-16080-4.

Correspondence and requests for materials should be addressed to H.K.J. or J.S.B.

Peer review information Nature Communications thanks Xiaofen Chen and the other anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020